Urgent Call for Action Against Antimicrobial Resistance: The Pasteur Act

Antimicrobial resistance (AMR) is emerging as a significant global health crisis, with approximately one in six bacterial infections now resistant to antibiotics. A major analysis published in *The Lancet* projects that antibiotic resistance could lead to nearly 170 million deaths worldwide over the next 25 years. This alarming trend is exacerbated by a dwindling pipeline of effective antibiotics, with only five of the 90 antibiotics currently in development targeting the World Health Organization's "critical priority" pathogens. The situation is dire, as drug-resistant bacteria are already responsible for over a million deaths annually.

The Hill

The economic landscape for antibiotic development is fraught with challenges. The inherent nature of antibiotics, which allows surviving microbes to mutate and develop resistance, necessitates their judicious use. This prudent approach, while essential for mitigating resistance, results in a limited market for antibiotics. Consequently, pharmaceutical companies face significant financial hurdles; developing a single antibiotic can take over a decade and cost upwards of $1 billion, with estimates indicating a negative return on investment of $50 million. These economic realities have led many large biopharmaceutical companies to withdraw from antibiotic development, leaving small biotech firms struggling to survive.

The Hill

In response to this urgent crisis, a bipartisan group of U.S. legislators has reintroduced the Pasteur Act, which aims to establish a new economic model for antibiotic development. This proposed legislation would create a subscription-style agreement between the federal government and companies that successfully develop novel antimicrobials. Under this model, healthcare professionals would gain access to essential treatments, while companies would receive a predictable return on their investments, alleviating the financial pressures associated with antibiotic sales.

The Hill

The implications of failing to pass the Pasteur Act are severe. Without legislative support, the U.S. healthcare system could face escalating costs, with researchers estimating that improved access to new antibiotics could save the system $97 billion annually by 2050. Moreover, the lack of effective antibiotics poses significant risks to national security, as the absence of reliable treatments could leave the population vulnerable to biological threats.

The Hill

Phyllis Arthur, executive vice president and head of health care policy and programs at the Biotechnology Innovation Organization, emphasizes the urgency of the situation, stating that "if lawmakers don’t pass the Pasteur Act soon, they will put our economy, our national security, and countless lives in danger." The call for action is clear: the time to address antimicrobial resistance is now, before the consequences become irreversible.

The Hill

While the urgency of the antimicrobial resistance crisis is widely acknowledged, there remains a lack of consensus on the specific measures needed to effectively combat it. Some experts advocate for alternative funding models, while others emphasize the need for increased public awareness and education on antibiotic use. The ongoing debate highlights the complexity of the issue and the necessity for a multifaceted approach.

The Hill

• “The odds are stacked against developers.” — Phyllis Arthur, Executive Vice President, Biotechnology Innovation Organization

The Hill

• “Without effective ones, routine procedures like knee surgery and cesarean sections would pose deadly risks.” — Anonymous Health Care Policy Professional

The Hill

• “In short, we need to establish a new model for antibiotics that gives drug developers the financial assurance they need to carry these treatments across the finish line.” — Anonymous Health Care Policy Professional

The Hill

The Pasteur Act represents a critical opportunity for lawmakers to take decisive action against the looming threat of antimicrobial resistance, ensuring that effective treatments remain available for future generations.

The Hill